Skip to main content Accessibility help
×
Home

Combined continuous hormone replacement therapy: an update

  • Laurence C Udoff (a1) and Eli Y Adashi (a1)

Extract

A growing body of information now supports the theory that oestrogen replacement therapy can substantially eliminate or attenuate the complications incurred as a result of the menopause. In particular, data support the claim that oestrogen replacement therapy for postmenopausal women is associated with the relief of vasomotor symptoms, the prevention of osteoporosis and urogenital atrophy, a lowering of cardiovascular morbidity and mortality, improved cognitive functioning, and a lower incidence of Alzheimer's disease.

Copyright

Corresponding author

Department of Obstetrics and Gynecology, University of Utah, Suite 2B200, 50 North Medical Drive, Salt Lake City, Utah 84132, USA.

References

Hide All
1Upton, GV. Therapeutic considerations in the management of the climacteric. J Reprod Med 1984; 29: 7180.
2Session, DR, Kelly, AC, Jewelewicz, R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 1993; 59: 277–84.
3Mishell, DR. Estrogen replacement therapy: an overview. Am J Obstet Gynecol 1989; 161: 1825–27.
4Cauley, JA, Cummings, SR, Black, DM, Mascioli, SR, Seeley, DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163: 1338–44.
5Paganini-Hill, A, Henderson, VW. Estrogen replacement therapy and the risk of Alzheimer's disease. Arch Intern Med 1996; 156: 2213–17.
6Utian, WG, Schiff, I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1: 39.
7Ravnikar, VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332.
8Hemminiki, E, Brambilla, DJ, McKinlay, SM, Posner, JG. Use of estrogens among middle aged Massachusetts women. DICP 1991; 25: 418–23.
9Wren, BG, Brown, L. Compliance with hormonal replacement therapy. Maturitas 1991; 13: 1721.
10Flowers, CE, Wilborn, WH, Hyde, BM. Mechanisms of uterine bleeding in postmenopausal women receiving estrogen alone or with a progestin. Obstet Gynecol 1985; 61: 135–43.
11Marslew, U, Riis, BJ, Christiansen, C. Progestogens: therapeutic and adverse effects in early postmenopausal women. Maturitas 1991; 13: 716.
12Whitehead, MI, Hillard, TC, Crook, D. The role and use of progestogens. Obstet Gynecol 1990; 75: 559–76.
13Nachtigall, LE. Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol 1990; 4(S): 77s–80s.
14March, MS, Whitehead, MI. The practicalities of hormone replacement. Balliéres Clin Endocrinol Metab 1993; 7: 183202.
15Birkenfeld, A, Kase, NG. Menopause medicine: current treatment options and trends. Compr Ther 1991; 17: 3645.
16Lobo, RA, Pickar, JH, Wild, R, Walsch, B. Hirvonen for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95.
17Grey, AB, Cundy, TF, Reid, IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 1994; 40: 671.
18Staland, B. Continuous treatment with a combination of estrogen and gestagen. A way of avoiding endometrial stimulation. Acta Obstet Gynecol Scand Suppl 1985; 130: 29.
19Magos, AL, Brincat, M, Studd, JWW et al. Amenorrhea and endometrial atrophy with continuous oral estrogen and progesterone therapy in postmenopausal women. Obstet Gynecol 1985; 65: 496.
20Sporrong, T, Hellgren, M, Samsioe, G et al. Comparison of four continuously administered progestogen plus estradiol combinations for climacteric complaints. Br J Obstet Gynecol 1988; 95: 1042.
21Weinstein, L, Bewtra, C, Gallagher, JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162: 153.
22Williams, SR, Frenchek, B, Spsroff, L et al. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 1990; 162: 438.
23Hillard, TC, Siddle, NC, Whitehead, MI et al. Continuous combined conjugated equine estrogenprogestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histological diagnosis. Am J Obstet Gynecol 1992; 167: 1.
24Obel, EB, Munk-Jensen, N, Svenstrup, B et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16: 13.
25Rauch, U, Taubert, HD. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable doses. A preliminary study. Maturitas 1993; 17: 123.
26MacLennan, AH, MacLennan, A, Wenzel, S et al. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomized trial. Med J Aust 1993; 159: 102.
27Marsh, MS, Crook, D, Whitcroft, SIJ et al. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994; 83: 19.
28Archer, DF, Pickar, JH, Bottiglioni, F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686.
29Munk-Jensen, N, Ulrich, LG, Obel, EB et al. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoproteins in a two year placebo controlled trial. Am J Obstet Gynecol 1994; 171: 132.
30Voetberg, GA, Netelenbos, JC, Kenemans, P et al. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994; 79: 1465.
31Spaulding, CB. Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement. Fertil Steril 1994; 62: 1181.
32The Postmenopausal Estrogen/Progestin Interventions Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199.
33Clisham, PR, deZiegler, D, Lozano, K et al. Comparison of sequential versus continuous estrogen and progestin replacement therapy in post-menopausal women. Obstet Gynecol 1991; 77: 241.
34Luciano, AA, DeSouza, MJ, Roy, MP et al. Evaluation of low dose estrogen and progestin therapy in post-menopausal women. J Reprod Med 1993; 38: 207.
35Weinstein, L. Efficacy of a continuous estrogenprogestin regimen in the menopausal patient. Obstet Gynecol 1987; 69: 929.
36Kable, WT, Gallagher, JC, Nachtigal, L et al. Lipid changes after hormone replacement therapy for menopause. J Reprod Med 1990; 35: 512.
37Nang, SL, Webster, MA, Wren, BG. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy. A study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust NZ J Obstet Gynaecol 1995; 35: 92.
38Yancey, MK, Stone, IK, Hannan, CJ. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990; 54: 778.
39Andersson, K, Mattsson, L, Rybo, G et al. Intrauterine release of levonorgestrel. A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963.
40Raudaskoski, TH, Lahti, El, Kauppila, AJ et al. Transdermal estrogen with a levonorgestrelreleasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114.
41Marslew, U, Riis, BJ, Christiansen, C. Bleeding patterns during continuous combined estrogen progestogen therapy. Am J Obstet Gynecol 1991; 164: 1163.
42Keller, PJ, Holtz, E, Imthrun, B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas 1992; 15: 195.
43Marslew, U, Overgaard, K, Riis, BJ et al. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: longterm effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992; 79: 202.
44Hargrove, JT, Maxson, WS, Wentz, AL et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73: 606.
45Prough, SG, Aksel, S, Wiebe, RH et al. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987; 157: 1449.
46Luciano, AA, Turksoy, RN, Carleo, J et al. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol 1988; 71: 39.
47Leather, AT, Savvas, M, Studd, JWW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1088.
48Holst, J, Cajander, S, von Schoultz, B. Endometrial effects of a continuous percutaneous oestrogen/low-dose oral progestogen regimen for climacteric complaints. Maturitas 1987; 9: 63.
49Oosterbaan, HP, van Burren, AJHAM, Schram, JHN et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995; 21: 211.
50Wolfe, BM, Huff, MW. Effects of continuous lowdosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women. Metabolism 1995; 44: 410.
51Christiansen, C, Riis, BJ. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins and bleeding pattern. Br J Obstet Gynaecol 1990; 97: 1087–92.
52Christiansen, C, Riis, BJ. 17-β estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 4: 836.
53Fuleihan, G, Brown, EM, Curtis, K. Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism. Arch Mem Med 1992; 152: 1904.
54Riis, BJ, Hohansen, J, Christiansen, C. Continuous oestrogen-progestogen treatment and bone metabolism in postmenopausal women. Maturitas 1988; 10: 51.
55Bewtra, C, Kable, WT, Gallagher, JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 1988; 32: 205–8.
56Farish, E, Fletcher, CD, Dagen, MM. Lipoprotein and apolipoprotein levels in post-menopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynaecol 1989; 96: 358–64.
57Mattson, LA, Callberg, G, Samsioe, G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric patients. Maturitas 1982; 4: 95102.
58Jensen, J, Riis, BJ, Strom, V, Christiansen, C. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987; 97: 130.
59Hawthorne, RJS. The endometrial status of women on long-term continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1991; 98: 939.
60Cano, A, Fernandes, H, Serrano, S, Mahiques, P. Effects on continuous oestradiolmedroxyprogesterone administration on plasma lipids and lipoproteins. Maturitas 1991; 13: 35.
61Metka, M, Hanes, V, Heytmanek, G. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen vs. oestrogen monotherapy. Maturitas 1992; 15: 53.
62Suhonen, SP, Holmstrom, T, Alonen, HO, Lahteenmake, P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63: 36.
63Denke, MA. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholestrolemic postmenopausal women. Am J Med 1995; 99: 29.
64Suvanto-Luukkonen, E, Sundstrom, H, Penttinen, J, Kauppila, A, Rutanen, EM. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995; 22: 255.
65Wollter-Svensson, LO, Stadberg, E, Andersson, K, Mattsson, LA, Odlind, V, Persson, I. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas 1995; 22: 199.
66Ainmelk, Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril 1996; 66: 962.
67Speroff, L, Rowan, J, Symons, J, Genant, H, Wilborn, W. The comparative effect on bone density, endometrium and lipids on continuous hormones as replacement therapy (CHART Study). JAMA 196; 276: 1397.
68Farish, E, Spowart, K, Barnes, JF, Fletcher, CD, Calder, A, Brown, A, Hart, DM. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions. Atherosclerosis 1996; 126: 77.
69Grey, A, Cundy, T, Evans, M, Reid, I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to estrogen in late postmenopausal women. Clin Endocrinol 196; 44: 293–96.
70Kalogirou, D, Antoniou, G, Karakitsos, P, Kalogirou, O, Antoniou, D, Giannikos, L. A comparative study of the effects of an estradiolreleasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Int J Fertil 1996; 41: 522–27.
71Tilly-Kiesi, M, Lappi, M, Puolakka, J, Luotola, H, Pyorala, T, Taskinen, MR. Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on lowdensity lipoprotein subclasses. Eur J Clin Invest 1996; 26: 1125.
72Eiken, P, Kolthoff, N, Nielsen, SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19: 191.–193S.
73Ettinger, B, Li, D, Klein, R. Continuation of postmenopausal hormone replacement therapy; comparison of cyclic versus continuous combined schedules. Menopause 1996; 3: 185–89.
74Kupperman, HS. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Endocrinol Metab 1953; 13: 688703.
75Henderson, BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859.
76Harlap, S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992; 166: 1986.
77Woodruff, JD, Pickar, JH for The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213.
78The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996; 275: 370.
79Kurman, RJ, Kaminski, PF, Norris, HJ. The behavior of endometrial hyperplasia: a long term study of ‘untreated’ hyperplasia in 170 patients. Cancer 1985; 56: 403.
80Gelfand, MM, Ferenczy, A. A prospective 1-year study of estrogen and progestin in postmenopausal women. Obstet Gynecol 1989; 74: 398.
81Udoff, L, Langenberg, P, Adashi, EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306.
82Bush, TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Kerenman, SG (ed) The menopause: biological and clinical consequences of ovarian failure; evolution and management. Serono Symposia, Norwell, Mass., 1990, p. 211.
83Stampfer, MJ, Colditz, GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47.
84Grady, D, Rubin, SM, Petitti, DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016.
85Shahar, E, Folsom, AR, Soloman, W et al. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996; 96: 1970.
86Gebara, OL, Mittleman, MA, Sutherland, P, Lipinska, I. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952.
87White, RE, Darkow, DJ, Lang, JL. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995; 77: 936.
88Stevenson, JL. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995; 49: 87.
89Tikkanen, MK, Kuusi, T, Nikkila, EA, Sipinen, S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas 1986; 8: 7.
90Newnham, HH. Oestrogens and atherosclerotic vascular disease: lipid factors. Ballieres Clin Endocrinol Metab 1993; 7: 61.
91Psaty, BM, Hackbert, SR, Atkins, D, Lemaitre, R et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women. Arch Intern Med 1994; 154: 1333.
92Falkeborn, M, Persson, I, Adami, HO et al. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821.
93Grodstein, F, Stampfer, MJ, Manson, JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 336: 453.
94Andersson, K, Stadberg, E, Mattsson, LA, Rybo, G. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 months of treatment. Int J Fertil 1996; 41: 476.
95Taskinen, MR, Puolakka, J, Pyorala, T, Luotola, H, Bjorn, M, Kaariainen, J, Lahdenpera, S, Ehnholm, C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Arterioscler Thrombo Vase Biol 1996; 16: 1215–21.
96Lobo, RA. Effects of hormonal replacement on lipids and lipoproteins in post-menopausal women. J Clin Endocrinol Metab 1991; 73: 925–30.
97Udoff, L, Adashi, EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 869.
98Bass, KM, Newschaffer, CJ, Klag, MJ, Bush, TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153: 2209–16.
99Glueck, CJ, Lang, J, Hamer, T, Tracy, T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 5964.
100Tikkanen, MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996; 23: 209–16.
101Stevenson, JC, Crook, D, Godsland, IF et al. Oral versus transdermal hormone replacement therapy. Int J Fertil 1993; 38(suppl): 3035.
102Maher, VMG, Brown, BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229235.
103Berglund, L. Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995; 6: 4856.
104Meilhahn, EN, Kuller, LH, Matthews, KA, Stein, EA. Lp(a) concentrations in pre- and postmenopausal women over time: the Healthy Women Study. Circulation 1991; 84(suppl): 112170.
105Andersson, B, Mattson, LA, Hahn, L, Maria, P, Lapidus, L, Holm, G, Bengtsson, BA, Bjorntorp, P. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitis. J Clin Endocrinol Metab 1997; 82: 638–43.
106Wilcox, JG, Hwany, J, Hodis, HN, Sevanian, A, Stomczyk, FZ, Lobo, RA. Cardioprotective effects of individual conjugated equine estrogen through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 1997; 67: 5762.
107Lindheim, SR, Presser, L, Ditkoff, E, Vijod, MA, Staczyk, FZ, Lobo, RA. A possible bimodal effect of estrogen in insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–67.
108Wagner, JD, Martino, MA, Jayo, MJ, Anthony, MS, Clarkson, JB, Cefalu, WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 1996; 45: 1245–62.
109Daly, E, Vesky, MP, Hawkins, MM, Carson, JC, Gough, P, Marsh, S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80.
110Jick, H, Derby, LE, Myers, MW, Vasilakis, C, Newton, KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–87.
111Vanderbroucke, JP, Helmerhoest, FM. Risk of venous thrombosis with hormone replacement therapy. Lancet 1996; 348: 972.
112Simioni, P, Prandoni, P, Lensing, AW et al. The risk of recurrent venous thromboembolism in patients with an Arg-506- Glu mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399403.
113Ericksen, EF, Kassem, M, Langdahl, B. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996; 19: 179.–183S.
114Pacifici, R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.
115Whitehead, MI, Lobo, RA. Progestogen use in postmenopausal women. Consensus conference. Lancet; 2: 1243–44.
116The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996; 276: 1389–96.

Related content

Powered by UNSILO

Combined continuous hormone replacement therapy: an update

  • Laurence C Udoff (a1) and Eli Y Adashi (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.